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Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid
malignancies. As reported in this issue ofCell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support
selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.Cancer stem cells possess the capacity to
self-renew as well as generate the hetero-
geneous cancer cells that comprise
a tumor. Although the theory of cancer
stem cells was proposed nearly 50 years
ago, prospectively identifying cancer
stem cells remains a challenge, as does
killing these quiescent, chemoresistant
cancer stem cells. Myeloid cancers,
particularly chronic myeloid leukemia
(CML) and acute myeloid leukemia
(AML), have been useful model systems
in the establishment of cancer stem cells
(Wang and Dick, 2005). In this issue of
Cell Stem Cell, Lagadinou et al. (2013)
and Goff et al. (2013) find that small-
molecule inhibition of anti-apoptotic
BCL-2 family members selectively harms
leukemia cells that possess stem cell
properties.
Instead of using canonical cell surface
markers to identify leukemia stem cells
(LSCs), Lagadinou et al. apply a functional
approach. They hypothesize that LSCs,
being quiescent in nature, have lower
metabolic activity and thus lower reactive
oxygen species (ROS) production. The
authors profile primary AML cells for their
ROS levels and find that ROS-low cells
not only exhibit less proliferation and
a higher fraction of cells in G0, but also
exhibit an increased ability to engraft
in immunodeficient mice compared to
ROS-high cells. In order to identify a
mechanism underlying this phenomenon,
they perform RNA-seq on ROS-low and
ROS-high cells and find that the anti-
apoptotic BH3-only family member
BCL-2 is upregulated in ROS-low cells.
This finding is validated by qRT-PCR
and immunoblot analysis. Importantly,
Lagadinou et al. demonstrate that inhibit-
ing BCL-2 with the battle-tested BCL-2
family inhibitor ABT-263 (Roberts et al.,2012) selectively kills ROS-low cells
in vivo. In addition, ex vivo treatment of
AML cells with ABT-263 inhibits engraft-
ment of AML cells into NSG mice.
The authors’ exploitation of ROS
measurements to functionally identify
LSCs and BCL-2-dependent subsets is
both novel and potentially of great utility.
The perturbation of metabolism and
oxygen consumption by BCL-2 inhibition
may require further clarification, however.
It is known that in sensitive cells, BCL-2
inhibition can cause mitochondrial outer
membrane permeabilization (MOMP)
very rapidly (Del Gaizo Moore et al.,
2008). This permeabilization by itself
could cause significant perturbations in
oxidative phosphorylation and oxygen
consumption. Thus, it needs to be clari-
fied whether the metabolic effects of
BCL-2 inhibition observed by the authors
occur before or after MOMP.
Similar to Lagadinou et al., Goff et al.
find that inhibition of BCL-2 (and its family
members) selectively target LSCs in
primary human CML cells. Instead of
taking a functional approach, the authors
more traditionally define CML LSCs as
CD34+CD38+Lin. They find that isolated
human blast crisis (BC) LSCs trans-
planted into RAG/g/, which engraft
into the bone marrow, are more quiescent
and chemoresistant compared to those
that engraft at the tumor site, spleen, or
liver. Based on a fairly modest relative
increase in expression of anti-apoptotic
proteins (like BCL-2) in BC LSCs com-
pared to normal or chronic phase (CP)
CD34+CD38+Lin cells, the authors treat
the cells with sabutoclax, developed as
a pan-BCL-2 inhibitor. They observe that
BC progenitor cells are more sensitive to
sabutoclax compared to normal progen-
itor cells. Further, combination treatmentCell Stem Cellof serially transplanted CML cells with
dasatinab (a BCR/ABL tyrosine kinase
inhibitor) andsabutoclaxcausedamodest
increase in life span compared to
untreated or single-agent-treated animals
(median survival increased from75 days
to 85 days).
To verify that the observations are
truly a leukemia-stem-cell-based effect
of direct inhibition of BCL-2 family pro-
teins, a couple of issues may require
future clarification. First, it is not com-
pletely clear that the mechanism of in vivo
toxicity of sabutoclax is solely due to inhi-
bition of BCL-2 family proteins. This is
pertinent because gossypol, from which
sabutoclax was derived, exhibits mecha-
nisms of killing that are distinct from direct
inhibition of BCL-2 family proteins (van
Delft et al., 2006). In this respect, it will
be interesting to see whether at effective
doses sabutoclax induces thrombocyto-
penia in mammals in vivo. While thrombo-
cytopenia can be a problem clinically, it
is a useful in vivo biomarker of BCL-XL
inhibition because circulating platelets
have been found to be dependent on
BCL-XL for survival (Mason et al., 2007).
In addition, it is not clear whether these
results from BC CML cells can be
extended to stem cells from de novo
AML. In the former case, the authors iden-
tified their stem cells as bearing a CD34+/
CD38+ phenotype, while in the latter case,
the CD34+/CD38 population is more
commonly thought to bear the stem cells
(Wang and Dick, 2005).
An exciting, translational message that
emerges from both papers is that inhibi-
tion of BCL-2 is a promising approach to
the treatment of myeloid malignancies.
These results are consistent with prior
studies that found that bulk and stem-
like AML cells are more dependent on12, March 7, 2013 ª2013 Elsevier Inc. 269
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In TranslationBCL-2 than normal HSCs are, and are
therefore more sensitive to BCL-2 inhibi-
tion by small molecules (Konopleva
et al., 2006; Vo et al., 2012). This evidence
comes at a particularly propitious time
with the recent introduction of ABT-199
into clinical trials (Souers et al., 2013). As
discussed briefly above, the dose-limiting
toxicity of ABT-263 thrombocytopenia,
caused by the inhibition of BCL-XL, is
a particular problem in the treatment of
AML patients that usually already suffer
from thrombocytopenia. ABT-199, by
selectively targeting BCL-2, but not
BCL-XL, avoids this toxicity, likely making
its use in AML better tolerated. With the
identification of a therapeutic index and
elimination of a major toxicity, it would
seem that conditions are ripe for clinical270 Cell Stem Cell 12, March 7, 2013 ª2013testing of BCL-2 inhibition in myeloid
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